BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company,today announced that the Company will participate in Cowen's 43rd Annual Healthcare Conference on Monday, March 6th, 2023
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company,today announced that the Company will participate in two upcoming investor conferences: The Guggenheim Oncology
Four new indications added for tislelizumab and all nine approved indications now included in NRDL KYPROLIS included for the first time XGEVA successfully renewed BeiGene (NASDAQ: BGNE; HKEX:
Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology companytoday announced that the Company will participate in the J.P. Morgan 41st Annual Healthcare Conferenceon Monday, January